All In Biotech

Drug Trial Radar · NCT04556656

PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients With Early Stage of Huntington Disease

Last checked: Nov 19, 2026Latest source record: Mar 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 499 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

499

Actual

Start

Oct 16, 2020

Primary completion

Mar 14, 2023

Study completion Mar 21, 2024

Sponsor

Lead sponsor
PrileniaIndustry
Sponsor type
Industry
First posted
Sep 21, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of pridopidine 45mg twice daily (BID) in patients with early stage manifest Huntington Disease (HD).

Conditions

  • Huntington Disease

Interventions

  • PridopidineDrug

    Pridopidine hard gelatin capsule

  • PlaceboDrug

    Pridopidine-matching placebo hard gelatin capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Unified Huntington Disease Rating Scale-Total Functional Capacity (UHDRS-TFC) Score (mITT)Time frame: From baseline to Week 65
  2. Change From Baseline to Week 65 in the UHDRS TFC Score (ITT)Time frame: From baseline to Week 65.

Locations

58 sites in 11 countries. Site status is shown where the registry gives one.

  • Prilenia Investigational Site (Site 061)

    Davis, California

  • Prilenia Investigational Site (Site 051)

    San Diego, California

  • Prilenia Investigational Site (Site 343)

    Englewood, Colorado

  • Prilenia Investigational Site (Site 333)

    Washington D.C., District of Columbia

  • Prilenia Investigational Site (Site 160)

    Gainesville, Florida

  • Prilenia Investigational Site (Site 019)

    Tampa, Florida

  • Prilenia Investigational Site (Site 032)

    Atlanta, Georgia

  • Prilenia Investigational Site (Site 088)

    Chicago, Illinois

  • Prilenia Investigational Site (Site 029)

    Kansas City, Kansas

  • Prilenia Investigational Site (Site 083)

    Wichita, Kansas

  • Prilenia Investigational Site (Site 087)

    Louisville, Kentucky

  • Prilenia Investigational Site (Site 028)

    Baltimore, Maryland

  • Prilenia Investigational Site (Site 017)

    Boston, Massachusetts

  • Prilenia Investigational Site (Site 076)

    Boston, Massachusetts

  • Prilenia Investigational Site (Site 027)

    St Louis, Missouri

  • Prilenia Investigational Site (Site 037)

    Albany, New York

  • Prilenia Investigational Site (Site 002)

    New York, New York

  • Prilenia Investigational Site (Site 119)

    Durham, North Carolina

  • Prilenia Investigational Site (Site 089)

    Cincinnati, Ohio

  • Prilenia Investigational Site (Site 020)

    Columbus, Ohio

  • Prilenia Investigational Site (Site 006)

    Portland, Oregon

  • Prilenia Investigational Site (Site 018)

    Philadelphia, Pennsylvania

  • Prilenia Investigational Site (Site 031)

    Nashville, Tennessee

  • Prilenia Investigational Site (Site 199)

    Houston, Texas

  • Prilenia Investigational Site (Site 326)

    Richmond, Virginia

  • Prilenia Investigational Site (Site 096)

    Seattle, Washington

  • Prilenia Investigational site (Site 291)

    Innsbruck, Austria

  • Prilenia Investigational Site (Site 232)

    Halifax, Canada

  • Prilenia Investigational Site (Site 030)

    Calgary, Alberta, Canada

  • Prilenia Investigational Site (Site 048)

    Vancouver, British Columbia, Canada

  • Prilenia Investigational Site (Site 098)

    Montreal, Quebec, Canada

  • Prilenia Investigational Site (Site 388)

    Prague, Czechia

  • Prilenia Investigational Site (Site 385)

    Lille, France

  • Prilenia Investigational Site (Site 384)

    Marseille, France

  • Prilenia Investigational Site (Site 392)

    Paris, France

  • Prilenia Investigational Site (Site 234)

    Aachen, Germany

  • Prilenia Investigational Site (Site 379)

    Bochum, Germany

  • Prilenia Investigational Site (Site 377)

    Lübeck, Germany

  • Prilenia Investigational Site (Site 376)

    Münster, Germany

  • Prilenia Investigational site (Site 292)

    Taufkirchen, Germany

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.